oxybutynin and Multiple Sclerosis

oxybutynin has been researched along with Multiple Sclerosis in 9 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

Research

Studies (9)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Autonomic Dysreflexia

(NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Bladder Compliance

"Bladder compliance is the result of a mathematical calculation of the volume required for a unit rise of pressure measured during a cystometric filling.~Bladder compliance is calculated by dividing the volume change by the change in bladder pressure (mL/cmH2O).~Efficacy:~Net change of the bladder compliance from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Cystometric Bladder Capacity (CBC)

"Efficacy:~Net change of the cystometric bladder capacity (CBC) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Detrusor Pressure (Pdet)

"Efficacy:~Net change of the detrusor pressure (Pdet) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Incontinence Impact Questionnaire (IIQ-7)

"Efficacy:~Net change of the Incontinence Impact Questionnaire (IIQ-7) from baseline and 12 months.~The IIQ-7 is a 7-item short forms on a 4-point scale ranging from 0 Not at all to 3 Greatly.~Total IIQ-7 score ranges = 0 to 21 The total IIQ-7 score can therefore range from 0 to 21 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Maximum Flow Rate (Qmax)

"Efficacy:~Net change of the maximum flow rate (Qmax) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Postvoid Residual Volume (PVR)

"Efficacy:~Net change of the postvoid residual volume (PVR) from baseline and 12 months~Results:~Botulinum toxin A injection have increased postvoid residual urine volume in patients treated for bladder dysfunction.~Treat only patients who are willing and able to initiate catheterization post-treatment, if required, for urinary retention.~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Quality of Life Index (QoL-I)

"Efficacy:~Net change of the quality of life index (QoL-I) from baseline and 12 months. The QoL-I on a 7-point scale ranging from 0 Delighted to 6 Terrible. The QoL-I ranges 0 to 6~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Urinary Distress Inventory (UDI-6)

"Efficacy:~Net change of the UrinaryDdistress Inventory (UDI-6) from baseline and 12 months.~The UDI-6 is a 6-item short forms on a 4-point scale ranging from 0 Not at all to 3 Greatly.~The total UDI-6 score can therefore range from 0 to 18 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Void Volume

"Efficacy:~Net change of the void volume from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Trials

3 trials available for oxybutynin and Multiple Sclerosis

Other Studies

6 other studies available for oxybutynin and Multiple Sclerosis